Eloralintide has just entered phase 3 testing, which is typically the final stage of clinical trials before a company can apply for FDA approval
The structure reveals a closed conformation in which the peptide-binding region of the ECD interacts with the extracellular regions of the TMD
People havent flocked to compounded GLP-1s just because theyre available
People should not assume that weight change alone proves a treatment is heart-safe
TRIUMPH-4 Phase III: 28.7% weight loss at 68 weeks highest ever recorded.Retatrutide vs Semaglutide vs TirzepatideRetatrutide: 28.7% weight loss (68 wk) Triple agonist (GLP-1+GIP+GCGR)Tirzepatide (Mounjaro/Zepbound): 22.5% (72 wk) Dual agonist (GLP-1+GIP)Semaglutide (Wegovy/Ozempic): 15-17% (68 wk) GLP-1 onlyKey Clinical Results (April 2026)TRIUMPH-4 Phase III (Dec 2025): 28.7% body weight reduction, 71.2 lbs lost at 12mg doseTRANSCEND-T2D-1 (Mar 2026): 2.0% HbA1c reduction, 16.8% weight loss in type 2 diabetesPhase II (NEJM 2023): 24.2% weight loss at 48 weeks, no plateau observedFDA NDA submission: Q4 2026-Q1 2027Research-Grade RetatrutideBioInfinity Lab GLP3-R: 99%+ purity, third-party COA verified, GMP compliant
This game-changing patch helps your body burn an extra 500 calories daily while at rest, meaning if your baseline is around 2,000 calories, you could be torching up to 2,500
%25201.png)
